Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

Launched by YONSEI UNIVERSITY · Nov 5, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how the microbiome—tiny living organisms in our bodies—can help in understanding and treating urological cancers like prostate, renal cell, bladder, and ureter cancer. Researchers believe that examining the microbiome in various samples such as tissue, blood, stool, and urine can provide valuable information for diagnosing these cancers, tracking how they progress, and assessing how well treatments are working. The goal is to create a large database of microbiome information specifically for the Korean population, which could lead to more personalized and effective medical care for patients with these conditions.

To be eligible for this trial, participants must be diagnosed with one of the urological cancers mentioned and have had surgery for their condition at Severance Hospital between October 2020 and October 2030. They also need to agree to participate in the study and allow their health information to be used for research. This trial is still recruiting participants, and anyone involved can expect to contribute to important research that may improve cancer care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed as urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer)
• • Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2020.10 and 2030.10
• • Those who agree to give permission to use their human source information
• • Those who agree with this study
• Exclusion Criteria:
• • Those who do not agree with this study
• • Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making